egnite, Inc., a leading digital health company for cardiovascular care, announces the expansion of its portfolio with the integration of a custom module designed to help physicians and health systems identify patients with atrial fibrillation (AF), deemed to be at elevated risk of stroke and bleeding, who are potentially eligible for left atrial appendage closure (LAAC) therapy. This treatment is an alternative to blood thinners proven to reduce the risk of stroke in patients with non-valvular AF, a widespread condition among the aging population in the US.
Developed in collaboration with a global leader in medical device technologies, this custom module is integrated into CardioCare, egnite’s flagship solution for health systems. The technology leverages egnite’s advanced data processing to scan over 1,700 hospital codes, identifying potential LAAC patients with high precision and delivering insights to inform targeted care.
“This expansion helps us ensure appropriate patients have access to potentially lifesaving technologies, ensuring health equity in our communities,” said Dr. Rahul Sharma, structural heart interventional cardiologist. “Our program is now more efficient with this technology, identifying patients with AF that may be better suited to LAAC instead of blood thinners, resulting in expedited referral and treatment.”
CardioCare is a digital health solution that streamlines patient management, minimizes care variability, and optimizes revenue management for hospital systems. Over 50 leading health systems across the US use this platform to help identify and manage the most vulnerable cardiovascular patients in their system. To date, the CardioCare platform has delivered:
55% improvement in workflow efficiencies
25% increase in lifesaving therapies for structural heart patients
50% improvement in clinical trial enrollment at a participating site
“This expansion delivers a more streamlined and precise process for identifying and managing patients,” said Joel Portice, president and chief executive officer of egnite. “I look forward to seeing how this technology can help improve care for some of the most at-risk cardiovascular patients.”
